BeOne Medicines (ONC) Revenue (2015 - 2026)

BeOne Medicines (ONC) has reported Revenue for 12 consecutive years, with $1.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Revenue rose 35.46% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $5.7 billion (up 37.44% YoY), while the FY2025 annual figure was $5.3 billion, up 40.23% from the prior year.
• Revenue advanced to $1.5 billion in Q1 2026 per ONC's latest filing, from $1.5 billion in the prior quarter.
• Across five years, Revenue topped out at $1.5 billion in Q1 2026 and bottomed at $306.6 million in Q1 2022.
• Historically, Revenue has averaged $855.4 million across 5 years, with a median of $781.3 million in 2023.
• On a YoY basis, Revenue climbed as much as 127.73% in 2022 and fell as far as 49.39% in 2022.
• BeOne Medicines' Revenue stood at $380.1 million in 2022, then surged by 66.91% to $634.4 million in 2023, then surged by 77.78% to $1.1 billion in 2024, then jumped by 32.84% to $1.5 billion in 2025, then grew by 1.02% to $1.5 billion in 2026.
• Business Quant data shows ONC's Revenue at $1.5 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.4 billion in Q3 2025.